[1]李珺莹,李红.酪氨酸激酶及其抑制剂与免疫性皮肤病的研究进展[J].中国皮肤性病学杂志,2015,(01):93-95,100.[doi:10.13735/j.cjdv.1001-7089.2015.0093]
 LI Jun ying,LI Hong.Tyrosine Kinases and its Inhibitors in Immune Dermatologic Diseases[J].The Chinese Journal of Dermatovenereology,2015,(01):93-95,100.[doi:10.13735/j.cjdv.1001-7089.2015.0093]
点击复制

酪氨酸激酶及其抑制剂与免疫性皮肤病的研究进展
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2015年01期
页码:
93-95,100
栏目:
综述
出版日期:
2015-01-01

文章信息/Info

Title:
Tyrosine Kinases and its Inhibitors in Immune Dermatologic Diseases
作者:
李珺莹李红
天津市中医药研究院附属医院(长征医院)皮肤科,天津 300121
Author(s):
LI JunyingLI Hong
Department of Dermatology,Changzheng Hospital,Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital,Tianjin 300121,China
关键词:
酪氨酸激酶抑制剂免疫性皮肤病系统性硬化症银屑病
Keywords:
Tyrosine kinasesInhibitorsDermatologic diseasesSystemic sclerosisPsoriasis
分类号:
R 751
DOI:
10.13735/j.cjdv.1001-7089.2015.0093
文献标志码:
B
摘要:
酪氨酸激酶是一类催化蛋白质酪氨酸残基磷酸化的酶。他们是一系列细胞反应的信号传导途径中的关键因素。近来研究表明,酪氨酸激酶与系统性硬化症、银屑病、寻常型天疱疮、大疱性类天疱疮、皮肌炎和系统性红斑狼疮等免疫性皮肤病的发病关系密切。酪氨酸激酶抑制剂为这些患者提供了一类新的治疗方法。本文就与免疫性皮肤病密切相关的酪氨酸激酶信号通路和酪氨酸激酶抑制剂的临床应用进展作一综述。
Abstract:
Tyrosine kinases are enzymes that catalyze the phosphorylation of tyrosine residues on protein substrates.They are key components of signaling pathways that drive an array of cellular responses.Specific tyrosine kinases have recently been identified as critical to the pathogenesis of several immune dermatologic diseases including systemic sclerosis,psoriasis,pemphigous vulgaris,bullous pemphigoid,dermatomyositis and SLE.Inhibitors of tyrosine kinases are emerging as a novel class of therapy that may provide benefit in certain patient subsets.In this review,we highlight tyrosine kinase signaling implicated in immune dermatologic diseases and clinical development of tyrosine kinases inhibitors.

参考文献/References:

[1] Johnson LN.Protein kinase inhibitors:contributions from structure to clinical compounds[J].Q Rev Biophys,2009,42(1):1-40.
[2] Iwamoto N,Distler JH,Distler O.Tyrosine kinase inhibitors in the treatment of systemic sclerosis:from animal models to clinical trials[J].Curr Rheumatol Rep,2011,13(1):21-27.
[3] Varga J,Pasche B.Transforming growth factor beta as a therapeutic target in systemic sclerosis[J].Nat Rev Rheumatol,2009,5(4):200-206.
[4] Jessica Gordon,Robert Spiera.Tyrosine kinase inhibitors in the treatment of systemic sclerosis:the difficulty in interpreting proofofconcept studies[J].Int J Rheumatol,2011,(2011):842181.
[5] Guo L,Chen XX,Gu YY,et al.Lowdose imatinib in the treatment of severe systemic sclerosis:a case series of six Chinese patients and literature review[J].Clin Rheumatol,2012,31 (9):1395-1400.
[6] Tamaki Z,Asano Y,Hatano M,et al.Efficacy of lowdose imatinib mesylate for cutaneous involvement in systemic sclerosis:a preliminary report of three cases[J].Mod Rheumatol,2012,22(1):94-99.
[7] Tan J,Wei J.Ethnic difference may contribute to the efficacy of lowdose imatinib mesylate in systemic sclerosis[J].Clin Rheumatol,2013,32(1):149-150.
[8] Bournia VK,Evangelou K,Sfikakis PP.Therapeutic inhibition of tyrosine kinases in systemic sclerosis:a review of published experience on the first 108 patients treated with imatinib[J].Semin Arthritis Rheum,2013,42(4):377-390.
[9] Halin C,Fahrngruber H,Meingassner JG,et al.Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor[J].Am J Pathol,2008,173(1):265-277.
[10] Crawshaw AA,Griffiths CE,Young HS.Investigational VEGF antagonists for psoriasis[J].Expert Opin Investig Drugs,2012,21(1):33-43.
[11] Narayanan S,CallisDuffin K,Batten J,et al.Improvement of psoriasis during sunitinib therapy for renal cell carcinoma[J].Am J Med Sci,2010,339(6):580-581.
[12] Kato Y,Yamamoto T.Dramatic effect of sunitinib with rapid but transient improvement for psoriasis in a patient with metastatic renal carcinoma[J].J Dermatol,2013,40(12):1069-1070.
[13] Ricardo TPaniagua,David Fiorentino,Lorinda Chung,et al.Tyrosine kinases in inflammatory dermatologic diseases[J].J Am Acad Dermatol,2011,65(2):389-403.
[14] Overbeck TR,Griesinger F.Two cases of psoriasis responding to erlotinib:time to revisiting inhbition of epidermal growth factor receptor in psoriasis therapy[J].Dermatology,2012,(2):179-182.
[15] Oyama N,Kaneko F,Togashi A,et al.A case of rapid improvement of severe psoriasis during moleculartargeted therapy using an epidermal growth factor receptor tyrosine kinase inhibitor for metastatic lung adenocarcinoma[J].J Am Acad Dermatol,2012,66(6):e251-253.
[16] Chang BY,Zhao F,He X,et al.JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice[J].J Immunol,2009,183(3):2183-2192.
[17] Boy MG,Wang C,Wilkinson BE,et al.Doubleblind,placebocontrolled,doseescalation study to evaluate the pharmacologic effect of CP690,550 in patients with psoriasis[J].J Invest Dermatol,2009,129(9):2299-2302.
[18] Cheng H,Geist DE,Piperdi M,et al.Management of imatinibrelated exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour[J].Australas J Dermatol,2009,50(1):41-43.
[19] Nagai T,Karakawa M,Komine M,et al.Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment[J].Eur J Haematol,2013,91(3):270-272.
[20] Atalay F,Kizilkilic E,Ada RS.Imatinibinduced psoriasis[J].Turk J Haematol,2013,30(2):216-218.
[21] Saito M,Stahley SN,Caughman CY,et al.Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation[J].PLoS One,2012,7(12):e50696.
[22] Pretel M,Espana A,Marquina M,et al.An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris[J].Exp Dermatol,2009,18(9):771-780.
[23] Ameglio F,D Auria L,CordialiFei P,et al.Bullous pemphigoid and pemphigus vulgaris:correlated behaviour of serum VEGF,sEselectin and TNFalpha levels[J].J Biol Regul Homeost Agents,1997,11(4):148-153.
[24] Hofmann SC,Technau K,Muller AM,et al.Bullous pemphigoid associated with hypereosinophilic syndrome:simultaneous response to imatinib[J].J Am Acad Dermatol,2007,56(5):S68-72.
[25] Greenberg SA,Pinkus JL,Pinkus GS,et al.Interferonalpha/betamediated innate immune mechanisms in dermatomyositis[J].Ann Neurol,2005,57(5):664-678.
[26] Walsh RJ,Kong SW,Yao Y,et al.Type I interferon inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis[J].Arthritis Rheum,2007,56(11):3784-3792.
[27] Ronnblom L,Alm GV,Eloranta ML.Type I interferon and lupus[J].Curr Opin Rheumatol,2009,21(5):471-477.
[28] Xiong W,Lahita RG.Novel treatments for systemic lupus erythematosus[J].Ther Adv Musculoskelet Dis,2011,3(5):255-266.
[29] Zoja C,Corna D,Rottoli D,et al.Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease[J].Kidney Int,2006,70(1):97-103.
[30] Apostolidis L,Kahlert C,Siegmund A,et al.Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin,and concommittant sorafenib[J].Onkologie,2009,32(1-2):50-53.

更新日期/Last Update: 2015-01-25